BR112014005414A2 - aplicações terapêuticas de ectoína - Google Patents
aplicações terapêuticas de ectoínaInfo
- Publication number
- BR112014005414A2 BR112014005414A2 BR112014005414A BR112014005414A BR112014005414A2 BR 112014005414 A2 BR112014005414 A2 BR 112014005414A2 BR 112014005414 A BR112014005414 A BR 112014005414A BR 112014005414 A BR112014005414 A BR 112014005414A BR 112014005414 A2 BR112014005414 A2 BR 112014005414A2
- Authority
- BR
- Brazil
- Prior art keywords
- ectoin
- inflammation
- der
- apoptosis
- von
- Prior art date
Links
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 title abstract 6
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 3
- 230000004054 inflammatory process Effects 0.000 abstract 3
- KIIBBJKLKFTNQO-WHFBIAKZSA-N 5-hydroxyectoine Chemical compound CC1=N[C@H](C(O)=O)[C@@H](O)CN1 KIIBBJKLKFTNQO-WHFBIAKZSA-N 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000031972 neutrophil apoptotic process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
(de)die erfindung betrifft eine zusammensetzung enthaltend ectoin, hydroxyectoin und/oder ein salz, ester oder amid dieser verbindungen zur unterdrückung von anti-apoptotischen signalen auf neutrophile granulozyten und andere an entzündungen beteiligte zellen. die verzögerte apoptose der neutrophilen ist eine hauptkomponente für verschiedene arten von entzündungen. durch verabreichung von ectoin wird eine zumindest partielle wiederherstellung der normalen apoptoserate erreicht, was mit einer entsprechenden verbesserung der entzündungserscheinungen verbunden ist. ---------------------------------------------------------------------------- tradução do resumo resumo patente de invenção: "aplicações terapêuticas de ectoína". a invenção se refere a uma composição contendo ectoína, hidroxiectoína e/ou um sal, éster ou amida desses compostos para suprimir sinais antiapoptóticos em granulócitos neutrófilos e outras células envolvidas em inflamações. a apoptose retardada dos neutrófilos é um componente principal para diversos tipos de inflamações. através da administração de ectoína obtém-se uma restauração pelo menos parcial da taxa de apoptose normal, que está associada com uma corresponde melhora dos sintomas de inflamação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011113059A DE102011113059A1 (de) | 2011-09-09 | 2011-09-09 | Therapeutische Anwendungen von Ectoin |
PCT/EP2012/003757 WO2013034299A1 (de) | 2011-09-09 | 2012-09-07 | Therapeutische anwendungen von ectoin |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014005414A2 true BR112014005414A2 (pt) | 2017-04-04 |
Family
ID=47115708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014005414A BR112014005414A2 (pt) | 2011-09-09 | 2012-09-07 | aplicações terapêuticas de ectoína |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140315869A1 (pt) |
EP (2) | EP2753330B1 (pt) |
JP (2) | JP6250542B2 (pt) |
CN (1) | CN103857394A (pt) |
BR (1) | BR112014005414A2 (pt) |
CA (1) | CA2848010A1 (pt) |
DE (1) | DE102011113059A1 (pt) |
ES (2) | ES2795879T3 (pt) |
IN (1) | IN2014CN02458A (pt) |
PL (2) | PL2753330T3 (pt) |
RU (1) | RU2648475C2 (pt) |
WO (1) | WO2013034299A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160106747A1 (en) * | 2008-01-30 | 2016-04-21 | Bitop Ag | Treating postoperative mechanical stress with an ectoine |
DE102008039231A1 (de) | 2008-08-22 | 2010-02-25 | Bitop Ag | Verwendung von Glucosylglycerol |
DE102014007423A1 (de) * | 2014-05-22 | 2015-11-26 | Bitop Ag | Zusammensetzung zur Behandlung des Auges |
DE102014113781A1 (de) * | 2014-09-23 | 2016-03-24 | Bitop Ag | Solut und Solutgemisch sowie eine Zusammensetzung enthaltend mindestens ein Solut zur Verwendung bei der Prävention oder Behandlung von durch Schwebstaub verursachter kosmetischer oder pathologischer Effloreszenzen |
DE102015121050A1 (de) * | 2015-12-03 | 2017-06-08 | Bitop Ag | Kompatibles Solut oder Solutgemisch zur Verwendung bei der Prävention oder Behandlung von Krankheiten mit Barrieredefekten in Epithelgeweben |
DE102016104470A1 (de) | 2016-03-11 | 2017-09-14 | Bitop Ag | Zusammensetzung zur Förderung der Aktivität von Sirtuinen |
US20210154119A1 (en) * | 2018-04-05 | 2021-05-27 | Shiseido Company, Ltd. | Asmt expression promoter |
CN114425056A (zh) * | 2020-10-14 | 2022-05-03 | 宁波希诺赛生物科技有限公司 | 一种用于改善哮喘的干细胞外泌体组合物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4244580A1 (de) | 1992-12-31 | 1994-07-07 | Galinski Erwin A | Verfahren zur in vivo Gewinnung von Inhaltsstoffen aus Zellen |
DE4342560A1 (de) * | 1993-12-14 | 1995-06-22 | Marbert Gmbh | Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten |
EP2258183A1 (en) * | 1998-12-22 | 2010-12-08 | The University of North Carolina at Chapel Hill | Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs |
ATE247981T1 (de) * | 1999-06-12 | 2003-09-15 | Bitop Ag | Proteinenthaltende pharmazeutische zubereitung |
DE10006578C2 (de) * | 2000-02-14 | 2002-10-31 | Bitop Ag | Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren |
DE10065986A1 (de) | 2000-12-21 | 2002-07-11 | Bitop Gmbh | Kompatible Solute als Stabilisatoren für Impfstoffe und Vakzine |
DE10330243A1 (de) | 2003-07-03 | 2005-01-20 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis |
DE10330768A1 (de) | 2003-07-07 | 2005-02-24 | bitop Aktiengesellschaft für biotechnische Optimierung | Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung |
DE102006056766A1 (de) | 2006-12-01 | 2008-06-05 | Bitop Ag | Verwendung von kompatiblen Soluten |
DE102007040615A1 (de) * | 2007-08-27 | 2009-03-05 | Bitop Ag | Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen |
-
2011
- 2011-09-09 DE DE102011113059A patent/DE102011113059A1/de active Pending
-
2012
- 2012-09-07 JP JP2014528897A patent/JP6250542B2/ja active Active
- 2012-09-07 US US14/343,017 patent/US20140315869A1/en not_active Abandoned
- 2012-09-07 CA CA2848010A patent/CA2848010A1/en not_active Abandoned
- 2012-09-07 RU RU2014113906A patent/RU2648475C2/ru not_active IP Right Cessation
- 2012-09-07 PL PL12780649T patent/PL2753330T3/pl unknown
- 2012-09-07 EP EP12780649.5A patent/EP2753330B1/de active Active
- 2012-09-07 ES ES17189829T patent/ES2795879T3/es active Active
- 2012-09-07 EP EP17189829.9A patent/EP3287131B1/de active Active
- 2012-09-07 WO PCT/EP2012/003757 patent/WO2013034299A1/de active Application Filing
- 2012-09-07 BR BR112014005414A patent/BR112014005414A2/pt not_active Application Discontinuation
- 2012-09-07 CN CN201280049557.3A patent/CN103857394A/zh active Pending
- 2012-09-07 ES ES12780649.5T patent/ES2657907T3/es active Active
- 2012-09-07 PL PL17189829T patent/PL3287131T3/pl unknown
- 2012-09-07 IN IN2458CHN2014 patent/IN2014CN02458A/en unknown
-
2017
- 2017-07-07 JP JP2017133770A patent/JP6396544B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2013034299A1 (de) | 2013-03-14 |
PL3287131T3 (pl) | 2020-10-19 |
PL2753330T3 (pl) | 2018-05-30 |
CA2848010A1 (en) | 2013-03-14 |
JP2014526448A (ja) | 2014-10-06 |
RU2014113906A (ru) | 2015-10-20 |
US20140315869A1 (en) | 2014-10-23 |
EP3287131A1 (de) | 2018-02-28 |
JP6250542B2 (ja) | 2017-12-20 |
EP3287131B1 (de) | 2020-03-04 |
JP2017197569A (ja) | 2017-11-02 |
IN2014CN02458A (pt) | 2015-08-07 |
ES2657907T3 (es) | 2018-03-07 |
RU2648475C2 (ru) | 2018-03-26 |
ES2795879T3 (es) | 2020-11-25 |
CN103857394A (zh) | 2014-06-11 |
JP6396544B2 (ja) | 2018-09-26 |
EP2753330B1 (de) | 2017-11-08 |
EP2753330A1 (de) | 2014-07-16 |
DE102011113059A1 (de) | 2013-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014005414A2 (pt) | aplicações terapêuticas de ectoína | |
PH12015501116A1 (en) | New indanyloxydihydrobenzofuranylacetic acids | |
WO2015038939A3 (en) | Modulators of complement factor b | |
PH12014502141A1 (en) | New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists | |
CL2017003245A1 (es) | Derivados de piperidina 1,4-sustituidos | |
MX2014013499A (es) | Moduladores alostericos de receptor alfa 7 nicotinico de acetilcolina, sus derivados y usos de los mismos. | |
PH12015502324A1 (en) | Synergistic compositions | |
BR112013022565A2 (pt) | fecho e processo para a produção de um fecho | |
UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
BR112014016808A8 (pt) | composições de biguanida e métodos de tratamento de distúrbios metabólicos | |
BR112015003371B8 (pt) | Composição para materiais ópticos, método para produzir um material óptico, material óptico, lente óptica, e, método para produzir uma composição para materiais ópticos | |
BR112012031873A2 (pt) | antagonistas de ciclo-hexil-azetidinila do ccr2 | |
BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
BR112015008297A2 (pt) | antagonistas de mglu2/3 para o tratamento de distúrbios autistas | |
TN2013000529A1 (en) | Trpm8 antagonists and their use in treatments | |
BR112015003729A8 (pt) | Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
BR112014018655A8 (pt) | Composto de 1h-indazol-3-carboxamida, e, composição farmacêutica | |
AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
NZ754764A (en) | Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses | |
BR112013032280A2 (pt) | membro coberto com revestimento duro | |
PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
BR112014006473A2 (pt) | composição e método para tratamento de uma doença autoimune | |
UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
NZ729455A (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
BR112012031470A2 (pt) | antagonistas de ciclo-hexil-azetidinila de ccr2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |